CRISPR
IPO- Type
- Public
About
A Basel, Switzerland and Boston, MA-based biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure serious human genetic diseases